EM1510I "HDL Function: Redefining the HDL Hypothesis for the 21st Century" (IM GR-102315)
The purpose of this presentation is to review the emerging evidence that HDL cholesterol levels do not adequately predict atherosclerotic risk and response to therapy in part because they do not adequately reflect HDL function. The presentation illustrates how measurement of HDL function, in particular cholesterol efflux, is a better marker of atherosclerotic risk and perhaps a better therapeutic target.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Increase awareness that HDL cholesterol levels do not adequately predict disease and response to HDL-modifying therapies.
- Describe the concept of HDL’s central role in reverse cholesterol transport and its relevance to atherosclerosis.
- Familiarize the audience with the measurement of cholesterol efflux and its association with atherosclerotic disease in humans.
- Highlight the effects of previous and ongoing therapeutics on cholesterol efflux.
Anand Rohatgi, M.D., M.S.C.S., F.A.C.C., F.A.H.A.
Associate Professor of Internal Medicine
Division of Cardiology
- 1.00 AMA